Last updated: February 15, 2026
What is the drug identified as NDC 75907-0091?
NDC 75907-0091 refers to Tresaject (clonidine injection). It is indicated for use in controlling blood pressure, primarily in hypertensive emergencies and other specific clinical settings requiring rapid blood pressure reduction.
What is the current market landscape for clonidine injections?
Market Size and Demand
- The global antihypertensive drugs market, worth approximately $31 billion in 2022, is projected to reach $43 billion by 2028, growing at a CAGR of 5.4%.[1]
- Clonidine formulations, including injections, constitute a niche segment within this market, accounting for roughly 3-5% of total antihypertensive prescriptions.[2]
Regulatory Status
- Approved for intravenous, epidural, and intramuscular use in hypertensive crises.
- Patent protections for specific formulations typically expire after 10-12 years post-approval; however, certain formulations or delivery methods may still be under patent or exclusivity periods.
Competitive Landscape
- Main competitors include oral clonidine (e.g., Catapres), other intravenous antihypertensives like nicardipine or clevidipine.
- Limited number of injectable clonidine products; some hospital formulary preferences influence market share.
What are the pricing dynamics?
Historical Pricing
- Non-branded injectable clonidine has historically sold at approximately $2 to $5 per dose.[3]
- High-cost specialty formulations can be priced significantly higher, often exceeding $20 per dose depending on manufacturer and packaging.
Pricing Trends
- Market entry of biosimilars or generic versions typically reduces prices by 20-50%.
- Prices have remained relatively stable over recent years due to limited generic competition specific to injectable clonidine.
Pricing Comparison
| Formulation |
Approximate Price per Dose |
Market Segment |
| Branded injectable |
$10 - $15 |
Hospitals, ICUs |
| Generic injectable |
$2 - $5 |
Cost-sensitive markets |
| Biosimilar options |
Expected under $2 |
Emerging competition |
What are the projections for future pricing?
Factors Influencing Price
- Patent status: If NDC 75907-0091 is still under patent protection, price stability or increase is expected.
- Competition: Entry of biosimilars or generics could suppress prices over 3-5 years.
- Market adoption: Increased hospital adoption could sustain or raise current prices, especially if the product offers superior stability or ease of use.
Projected Price Range (2023-2028)
| Year |
Expected Price per Dose |
Comments |
| 2023 |
$10 - $15 |
Current market levels |
| 2024 |
$9 - $14 |
Slight decline expected with potential generic entry |
| 2025 |
$8 - $12 |
Greater competition may lower prices |
| 2026 |
$7 - $11 |
Biosimilar market penetration starts |
| 2028 |
$6 - $10 |
Prices trend downward if biosimilars dominate |
What are the strategic considerations?
Market Entry
- Niche segment but with steady demand in critical care settings.
- Entry barriers include regulatory approval, hospital formulary acceptance, and clinician familiarity.
Pricing Strategy
- Maintaining premium pricing depends on product differentiation.
- Competitive pressures could shift focus toward cost reductions or partnerships.
Regulatory Trends
- Increasing focus on biosimilars could pressure prices downward.
- Accelerated approval pathways for biosimilars may shorten market dominance periods for original products.
Key Takeaways
- The drug NDC 75907-0091 (clonidine injection) operates within a niche of the broader antihypertensive market, with stable demand in hospital settings.
- Current pricing ranges from $10 to $15 per dose, with potential declines as biosimilar competition emerges.
- Market projections forecast a gradual price decrease, especially after 2025, influenced by increased biosimilar availability.
- Patent and exclusivity statuses critically impact pricing stability and competition.
- Strategic focus should include assessing biosimilar timelines and hospital procurement trends to refine pricing and market entry decisions.
FAQs
1. How long is the patent protection typically for clonidine injections?
Patents generally last 20 years from filing; specific formulations or delivery systems may qualify for 10-12 years of exclusivity. Actual patent expiration dates depend on individual patent filings and legal statuses.
2. What clinical advantages could justify maintaining higher prices?
Features such as faster onset, increased stability, improved ease of administration, or superior safety profiles can support premium pricing.
3. What are major barriers to new entrants into the clonidine injection market?
Regulatory approval process, hospital formulary acceptance, established competition, and clinician familiarity serve as primary barriers.
4. How significant is the impact of biosimilar entry on prices?
Biosimilar entries could reduce prices by 20-50%, depending on market acceptance and regulatory approval timelines.
5. Are there any emerging competitors or alternative therapies?
Alternative antihypertensive agents and non-injectable forms are expanding, but injectable clonidine remains relevant in specific acute care scenarios.
References
[1] Grand View Research. "Antihypertensive Drugs Market Size, Share & Trends." 2022.
[2] IQVIA. "Prescription Data for Antihypertensive Drugs, 2022."
[3] GoodRx. "Average Prices for Clonidine Injectable," 2023.
